You just read:

European Medicines Agency Issues Positive Opinion for the Use of IMBRUVICA® (ibrutinib) as a First-Line Treatment for Chronic Lymphocytic Leukemia Patients

News provided by

AbbVie

Apr 29, 2016, 09:19 ET